Despite controversy regarding the role of glucagon in metabolic disorders associated with diabetes, the recognized importance of hyperglucagonemia in the pathophysiology of T1D and T2D fostered the development of therapeutic strategies aimed at glucagon action reduction (165, 167). This evidence concerns the gene GCG and diabetes mellitus.